Article
Cell Biology
Zhiguo Niu, Jianing Fan, Fengzhe Chen, Huijie Yang, Xin Li, Ting Zhuang, Chunlei Guo, Qi Cao, Jian Zhu, Hui Wang, Qingsong Huang
Summary: Breast cancer is the most common malignancy in women globally. Abnormal expression of RBCK1 protein in breast tumors makes it a valuable diagnostic marker and drug target. Hypoxic regions in breast cancer activate the HIF1 pathway, influencing tumor recurrence and metastasis. Targeting RBCK1 could be a promising treatment strategy for ER-positive breast cancer.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Charly Jehanno, Pascale Le Goff, Denis Habauzit, Yann Le Page, Sylvain Lecomte, Estelle Lecluze, Frederic Percevault, Stephane Avner, Raphael Metivier, Denis Michel, Gilles Flouriot
Summary: Hormone receptor positive breast cancer often develops resistance to treatment, leading to metastatic relapses. Understanding the molecular mechanisms behind this resistance is crucial. Hypoxia, a common feature of solid tumors, has been shown to promote endocrine resistance by down-regulating estrogen receptor alpha (ER alpha) expression.
Review
Biochemistry & Molecular Biology
Lea Clusan, Francois Ferriere, Gilles Flouriot, Farzad Pakdel
Summary: Breast cancer, the most common and deadliest cancer among women worldwide, is closely associated with estrogen signaling. Hormone therapy using antiestrogens is the standard treatment, but resistance inevitably occurs through various biological mechanisms. Understanding the estrogen pathway is crucial for the development of new therapies for hormone-dependent breast cancer. This mini-review summarizes the current literature on estrogen receptors in breast cancer, including their signalization, mechanisms of action, and clinical implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Javier A. Menendez, Adriana Papadimitropoulou, Travis Vander Steen, Elisabet Cuyas, Bharvi P. Oza-Gajera, Sara Verdura, Ingrid Espinoza, Luciano Vellon, Inderjit Mehmi, Ruth Lupu
Summary: The study highlights the critical role of fatty acid synthase (FASN) in HER2-driven tamoxifen resistance and suggests that FASN inhibition could be a novel therapeutic approach to restore tamoxifen sensitivity in endocrine-resistant breast cancer.urther research using next-generation FASN inhibitors may be therapeutically relevant in countering resistance to tamoxifen in FASN-overexpressing ER+/HER2+ breast carcinomas.
Article
Chemistry, Medicinal
Chengfeng Bai, Shengnan Ren, Shuangjie Wu, Meiqi Zhu, Guoshun Luo, Hua Xiang
Summary: Endocrine therapy has been beneficial for breast cancer patients with ER alpha positive tumors for decades, but the development of resistance remains a challenge. The exploration of new ER alpha targeted agents is crucial to overcome therapy resistance and improve patient outcomes.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Endocrinology & Metabolism
Esmael Besufikad Belachew, Dareskedar Tsehay Sewasew
Summary: The estrogen receptor is crucial in the treatment of estrogen receptor-positive breast cancer, with endocrine resistance posing a challenge. Combining drugs that target different signaling pathways and coregulatory proteins with endocrine therapy may offer a novel therapeutic approach to combat endocrine resistance.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Lea Clusan, Pascale Le Goff, Gilles Flouriot, Farzad Pakdel
Summary: Breast cancer is the most common cancer among women worldwide. While most ER-positive breast cancer cases initially respond to antiestrogen therapies, a high percentage develop resistance over time. Research on mutated forms of ER alpha has led to potential developments in new antiestrogen treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Environmental Sciences
Juan P. Munoz, Rocio Araya-Osorio, Raul Mera-Adasme, Gloria M. Calaf
Summary: Recent reports have questioned the safety of glyphosate, the active ingredient in several herbicide formulations, suggesting that it may act as an endocrine disruptor by promoting estrogenic activity. This study aimed to investigate the mechanism by which glyphosate induces estrogenic effects using breast cancer cell line models. The results showed that high concentrations of glyphosate mimic the effects of estrogen, leading to the activation of estrogen receptor alpha and enhanced cell proliferation.
Review
Endocrinology & Metabolism
Angeles C. Tecalco-Cruz, Marina Macias-Silva, Josue Orlando Ramirez-Jarquin, Uri Nimrod Ramirez-Jarquin
Summary: This minireview highlights the molecular mechanisms involved in regulating ER alpha stability and nucleocytoplasmic transport, providing information for novel biomarkers, therapeutic targets, and promising strategies in breast cancer treatment.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Multidisciplinary Sciences
Christopher Jackson, Alexandra L. J. Freeman, Zsofia Szlamka, David J. Spiegelhalter
Summary: This meta-analysis identified and quantified a range of potential adverse effects associated with bisphosphonate drugs in breast cancer patients, most of which are clinically recognized. The study showed that bisphosphonate drugs may lead to various adverse effects, but there was little variation in side effects between patients of different ages, menopausal status, cancer types, and concurrent breast cancer therapies.
Review
Cell Biology
Fiona H. Zhou, Teesha Downton, Allegra Freelander, Joshua Hurwitz, C. Elizabeth Caldon, Elgene Lim
Summary: CDK4/6 inhibitors have revolutionized the treatment of ER+ breast cancer and are the standard first-line therapy. However, resistance to these inhibitors is a challenge and there is a need to understand the mechanisms of resistance to guide subsequent treatment decisions.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Oncology
Zsuzsanna Nagy, Rinath Jeselsohn
Summary: Breast cancer is the most common female malignant tumor and the leading cause of cancer death in women worldwide. Hormone receptor positive (ER+) breast cancer is the most common subtype, and current treatment includes targeting the estrogen receptor with endocrine therapy (ET). However, resistance to ET is a major challenge for ER+ breast cancer patients, leading to disease recurrence or progression.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Eliot B. Blatt, Noa Kopplin, Shourya Kumar, Ping Mu, Suzanne D. Conzen, Ganesh Raj
Summary: Prostate cancer and breast cancer are both hormone-dependent cancers that rely on androgen receptor and estrogen receptor for growth, and resistance to endocrine therapy is common due to enhanced signaling through overexpression, mutation, or splicing of the receptors, coregulator alterations, and increased hormonal synthesis. Therapeutic strategies for targeting advanced PCa and BCa should take into account the differences in mechanisms of antiandrogen and antiestrogen resistance.
ENDOCRINE-RELATED CANCER
(2021)
Article
Oncology
Zheqi Li, Tianqin Li, Megan E. Yates, Yang Wu, Amanda Ferber, Lyuqin Chen, Daniel D. Brown, Jason S. Carroll, Matthew J. Sikora, George C. Tseng, Steffi Oesterreich, Adrian V. Lee
Summary: The EstroGene database was established to analyze the activation of estrogen receptor -a (ER/ESR1) in breast cancer cell lines. It provides a user-friendly browser for gene inquiry and data visualization. The study revealed bidirectional E2 regulation in certain genes and characterized the E2 response programs in MCF7 and T47D cell lines.
Article
Cell Biology
Xiaohong Xia, Chuyi Huang, Yuning Liao, Yuan Liu, Jinchan He, Zhenlong Shao, Tumei Hu, Cuifu Yu, Lili Jiang, Jinbao Liu, Hongbiao Huang
Summary: The study highlights the importance of deubiquitinase USP15 in preventing ERα degradation and promoting breast cancer progression. Knockdown of USP15 enhances the antitumor activities of tamoxifen on breast cancer cells. These findings provide a new approach to overcoming resistance to endocrine therapy and targeting the USP15-ERα axis for therapeutic strategies on ERα degradation.
CELL DEATH & DISEASE
(2021)